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1 Appraisal Processes for Cancer Drugs
The European Medicines Agency (EMA) began operating
in 1995 with the aim of evaluating the clinical efficacy and
safety of new medicines prior to their entry into the
European Union (EU) market. In addition, the EMA
ensures that the benefits of the medicines authorised for use
in the EU outweigh their risks by continuing to monitor
their safety after approval through their pharmacovigilance
programme [1].
Recently, Davis et al. [2] reported that the majority of
oncology drugs approved by the EMA between 2009 and
2013 were ‘‘…without evidence of benefit on survival or
quality of life’’ [2]. The authors reported that, at the time of
EMA assessment, significant prolongation of survival was
reported for 24 out of 68 indications (35%) and there was
an improvement in quality of life for seven out of 68
indications (10%). The clinical benefit of the new drugs
remained uncertain for 33 out of 68 indications (49%) after
a median follow-up of 5.4 years post-marketing authori-
sation [2].
In England, the National Institute for Health and Care
Excellence (NICE) has a mandate to appraise drugs
approved by the EMA in a timely fashion with a view to
making recommendations regarding their routine use in the
National Health Service (NHS) [3]. This mandate makes it
necessary for NICE appraisals to be undertaken using the
data available at the time of, or near the point of, regulatory
approval. The level of evidence that informs the EMA’s
conclusion of a positive benefit/risk balance therefore plays
a large part in determining the level of uncertainty present
in each NICE appraisal.
Evidence submissions from the sponsors of new oncol-
ogy drugs to NICE are critiqued by independent Evidence
Review Groups (ERGs) and subsequent recommendations
for use are made by one of the four NICE appraisal com-
mittees. In this commentary, authored by representatives of
the nine ERGs, we report the results of our comparison of
the oncology drugs approved by the EMA between 2009
and 2013 [2] and the appraisal decisions made by NICE in
the Single Technology Appraisal (STA) process. We then
reflect on the newly revised Cancer Drugs Fund (CDF) [4]
and highlight some of the challenges that we feel policy
makers may face in the future.
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2 Methods
Electronic searches were conducted using the NICE guid-
ance website [5] to identify the drugs approved by the
EMA for oncology indications between 2009 and 2013. We
then determined how many of these drugs had been con-
sidered as part of the NICE appraisal process and recorded
the resultant decisions taken by the NICE appraisal com-
mittee. Finally, we reviewed the CDF listings [6] to iden-
tify how many of these drugs were available to the NHS
through this fund.
Data extracted included the NICE appraisal committee
recommendation following publication of the final apprai-
sal determination, whether there were limitations in the
recommended use of the drug and if the drug was to be
provided at a discounted cost in the UK (e.g. via a patient
access scheme).
3 NICE Recommendations
The NICE appraisal committees can issue a number of
possible recommendations in any given appraisal. The
recommendations can be classified into the following cat-
egories [5]:
• recommended for use at the stated price or at a
discounted price offered by the sponsor of the
submission;
• recommended for optimised use, meaning that the
technology is only recommended for a subgroup of the
patients listed in the EMA marketing authorisation (e.g.
based on factors such as disease stage or progression, or
receipt of previous treatments);
• recommended for use within the new CDF;
• recommended for use only in research;
• not recommended.
A summary of the decisions taken by NICE related to
the 68 cancer indications for drugs that the EMA approved
between 2009 and 2013 is presented in Table 1. There are a
number of interesting issues to examine from these data.
NICE awarded a positive recommendation in 45 out of the
57 oncology indications (79%) that it did appraise. Of
these, eight (18%) received what is known as an optimised
recommendation. In addition, of the 45 positive recom-
mendations, 37 (82%) were for oncology drugs that were
recommended by NICE only when they were made avail-
able at a discounted price to the NHS. Finally, NICE did
not carry out an appraisal of 11 of the drugs approved by
the EMA between 2009 and 2013.
Therefore, it can be seen that the NICE appraisal process
is fulfilling its mandate through the application of rigorous
appraisal processes that take into consideration both clini-
cal and cost effectiveness whilst attempting to ensure that
patients receive effective treatments in a timely manner.
4 Referrals to the UK Cancer Drugs Fund
In an analysis of the UK CDF, Aggarwal et al. [7] (like
Davis et al. [2]) reported a lack of clinical benefit for the 29
cancer drugs approved for 47 indications that could have
been accessed through the CDF in January 2015. Aggarwal
et al. [7] concluded that ‘‘…the majority of CDF-approved
indications have been based on studies that reported min-
imal to no benefit in survival.’’
However, since July 2016, there has been a significant
change in the CDF with the responsibility for it shifting to
NHS England and NICE [8]. In the new process, NICE
refers a cancer drug to the CDF in situations where there is
a ‘plausible potential’ that, with additional data, the drug
could be recommended for routine commissioning in the
NHS [9]. The drug is then available to patients through the
fund and further data on effectiveness can be collected to
inform a new appraisal of the cost effectiveness of the
intervention at a future date, usually within 2 years of the
initial referral. Up until March 2018, NICE had referred a
total of 36 drugs (for 53 different indications) to the CDF.
Of the oncology treatments considered in this commentary,
a total of 15 drugs for 16 indications approved by NICE are
being monitored through the CDF.
5 Current Uncertainties
NICE has an important role as an assessor of both the
clinical and cost effectiveness of oncology drugs approved
for use by the EMA. However, as outlined by Woolacott
et al. [10], there are methodological challenges to assessing
effectiveness when the clinical evidence available to the
regulators is limited and/or immature. For example, there
has been an increase in the number of NICE appraisals
where the only clinical effectiveness data available for
consideration comes from single-arm, non-comparative
studies that often have small numbers of patients and
limited follow-up. Over the past year (i.e. March 2017 to
March 2018), there have been 14 such submissions that the
ERGs have been asked to critique. Having to make deci-
sions based on limited data invariably leads to assumptions
in economic models that consequently result in increased
uncertainty in the cost-effectiveness results, which is often
not appropriately reflected (i.e. not parameterised in the
model, not sufficiently explored in scenario analysis).
Given these complexities and the considerable uncertainty,
it is not clear whether all of the positive recommendations
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by NICE would be justified had more definitive data been
available, or whether such recommendations truly resulted
in improvements in patient outcomes.
We acknowledge that, given all of these uncertainties, it
is becoming more challenging for NICE and other national
HTA agencies to make recommendations about the adop-
tion of clinical- and cost-effective technologies. While all
HTA agencies continue to strive to improve their appraisal
processes, sponsors should be encouraged not only to
collect good quality clinical evidence over the long term
but also to make this information routinely available to
HTA agencies. There has been a recent victory in the
European Court of Justice allowing for the release of
clinical data by the EMA and there are hopes that there will
be further steps taken to improve the transparency of
clinical data [11].
In England, NICE is working hard to ensure that cancer
drugs with uncertain benefits are recommended for use
only when accompanied by careful monitoring via the new
CDF. The potential total benefits to patients of early access
to promising new treatments will be realised more quickly
than ever before. We welcome this approach as it means
that, where the benefits of new cancer drugs are uncertain
at the time of marketing authorisation, patient outcomes
can be monitored without denying patients early access to
these new treatments. Drugs in the CDF are to be reviewed
usually within a period of 2 years and will then undergo
further appraisal with only cost-effective drugs with proven
benefits being recommended for use in the NHS. It is of
note that the pathway to a CDF recommendation and
design of potential data collection is currently not clearly
defined. The inclusion of a formal step, in which the value
of data collection is assessed compared to its cost and the
cost of making the new drug available through the CDF,
may aid in ensuring the efficiency of the CDF.
As researchers responsible for critiquing evidence sub-
missions to the NICE appraisal process, we find ourselves
facing increasing uncertainty:
– Uncertainty in the clinical data available as we note the
increase in the number of NICE appraisals that are
using data from small, single-arm studies with short-
term follow-up.
– Uncertainty in the way the newly introduced CDF
process will monitor the drugs approved through this
mechanism and how information will flow back into
the NICE appraisal process.
– Uncertainty due to potential changes in the NICE
appraisal process coming into effect in April 2018 that
include new roles for the NICE appraisal committees,
the NICE appraisal teams and the ERGs providing
critiques of the submitted evidence [12].
As regulatory authorities continue to approve cancer
drugs that have uncertain benefits at the time of licensing, it
increasingly becomes the responsibility of every national
HTA agency to ensure that the post-marketing survival
benefits of these drugs are closely monitored. Indeed,
willingness to address these uncertainties must be a priority
for all parties involved in HTA.
Of course, added to this, there is the uncertainty of how
medicines will be licensed in the UK following departure
from the EU in 2019, and how, in turn, this will affect the
current NICE drug appraisal process [13].
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Table 1 NICE decisions for indications related to the cancer drugs approved by the EMA between 2009 and 2013
Outcome Positive
recommendation
Optimised
recommendation
Cancer Drugs
Fund
Total
Positive recommendation (at list price) 6 2 0 8
Positive recommendation at a discounted price 15 6 16 37
Not recommended 12
No NICE recommendation 11
No company submission [n = 3]
Unable to differentiate drug and indication on the NICE website
[n = 3]
Not referred to NICE [n = 2]
Suspended or discontinued [n = 2]
In progress [n = 1]
Total 21 8 16 68
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